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ABSTRACT
Introduction: The term progressive fibrosing
interstitial lung disease (ILD) describes patients
with fibrotic ILDs who, irrespective of the aeti-
ology of the disease, show a progressive course
of their disease despite current available (and
non-licensed) treatment. Besides in idiopathic
pulmonary fibrosis, little is known about man-
agement and the burden of patients with
fibrotic ILD, particularly those with a progres-
sive behaviour.
Methods: Using the Delphi method, 40 Euro-
pean experts in ILD management delivered
information on management of (progressive)
fibrosing ILD and on the impact of the disease
on patients’ quality of life (QoL) and healthcare
resource utilisation (HCRU). Annual costs were
calculated for progressive and non-/slow-pro-
gressive fibrosing ILD for diagnosis, follow-up
management, exacerbation management, and
end-of-life care based on the survey data.
Results: Physicians reported that progression in
fibrosing ILD worsens QoL in both patients and
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their caregivers. Progression of fibrosing ILD
was associated with a greater use of HCRU for
follow-up visits and maintenance treatment
compared with the non-/slow progression. The
number of patients who suffered at least one
acute exacerbation was reported to be more
than three times higher in progressive fibrosing
ILD patients than in patients with non-/slow-
progressive fibrosing ILD. On average, annual
estimated costs of progressive fibrosing ILD per
patient were 1.8 times higher than those of the
non-/slow-progressive form of the disease.
Conclusions: Progression in fibrosing ILD cau-
ses a significant impact on QoL and HCRU and
costs. These survey data underline the need for
safe and effective therapies to slow the disease
progression.
Keywords: Burden of disease; Consensus; Cost
study; Delphi; European countries; Interstitial
lung disease; Progressive fibrosing; Pulmonary;
Societal impact
Key Summary Points
Why carry out this study?
A significant number of patients with
fibrosing interstitial lung diseases (ILD)
show a progressive behaviour that may
lead to rapid health deterioration and
early death, but little is known about the
management and burden of these
progressive fibrosing ILD patients.
Disease progression in fibrosing ILD affects
patients’ quality of life and increases
healthcare resource use, and it is
estimated to cost 1.8 times more than the
non-progressive stage of fibrosing ILD.
What was learned from this study?
This Delphi study provides novel
information on experts’ management of
fibrosing ILD and estimates the burden of
disease of fibrosing ILD and the impact of
its progression.
INTRODUCTION
Fibrosing interstitial lung diseases (ILDs) form a
large and heterogeneous group of disorders that
cause fibrosis in the lung parenchyma [1]. The
most common form is idiopathic pulmonary
fibrosis (IPF), which is characterised by pro-
gressive fibrosis, decline in lung function, pro-
gressive worsening of dyspnoea, and early
mortality [2].
Despite differences in aetiology and clinical
presentation, other ILDs may develop with
progressive fibrosis and resemble IPF, with
decline of lung function, worsening of respira-
tory symptoms, and non-responsiveness to
treatment with anti-inflammatory or
immunomodulatory agents [1, 3, 4]. It has
recently been suggested that this progressive
fibrosing behaviour shares some similar biolog-
ical and clinical features and that patients with
ILD who present this behaviour can be grouped
as patients with progressive fibrosing ILD [3, 5].
The prevalence of progressive fibrosing ILD
other than IPF (non-IPF progressive fibrosing
ILD) is not known, but may be similar to the
prevalence of IPF [6, 7]. Recent studies have
suggested a prevalence in the European popu-
lation that ranges between 0.63–7.60/10,000 for
fibrosing ILD and between 0.5–6.72/10,000 for
non-IPF fibrosing ILD [7–10].
The socioeconomic burden of IPF is consid-
erable. IPF has a significant impact on daily
functioning and patients’ quality of life [11, 12]
and represents a substantial burden on the
healthcare system [13]. Similarly, non-IPF pro-
gressive fibrosing ILD impairs patients’ quality
of life and, because of its resemblance in
pathogenesis, is expected to increase the use of
healthcare resources and costs in a comparable
way [12, 14].
Overall, there is still little information on the
definition, management, and socioeconomic
burden of non-IPF progressive fibrosing ILD.
The aims of this study were to evaluate the
consensus among healthcare providers on the
concept and management of non-IPF progres-
sive fibrosing ILD and to estimate the burden of
disease of progression in non-IPF fibrosing ILD
in mid-sized European countries.
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METHODS
Study Design, Participants, and Delphi
Survey
The Burden of Interstitial Consensus Panel
(BUILDup) study used a modified Delphi
method to evaluate consensus on the definition
and management of progressive fibrosing ILD
and to estimate the impact and economic bur-
den of progression in non-IPF fibrosing ILD.
A brief description of the BUILDup study is as
follows: the Steering Committee included eight
members from six European countries: Belgium
(WW), Denmark (JRD), Finland (MK), Greece
(SP and EM), The Netherlands (JM), and Portu-
gal (AM and CRC). The Delphi questionnaire
(Appendix 1) was designed based on a Boolean
literature search in PubMed using ‘‘fibrosing’’
AND ‘‘interstitial lung disease’’ AND ‘‘progres-
sive’’ as search terms and on the clinical exper-
tise of the Steering Committee. A total of 138
panellists (about 15 per country) were contacted
to participate in the study. Invited panellists
were pulmonologists or rheumatologists with at
least 5 years of experience in their speciality and
in the management of patients with progressive
fibrosing ILD working in European public hos-
pitals. Panellists could answer the questionnaire
through an online platform. Two rounds of
voting were held between February and June
2019. The second round only included items for
which no consensus was reached in the first
round.
The definition of progression in fibrosing
ILD used in this analysis is the one of the
INBUILD trial [3, 15], albeit no results of the
INBUILD trial were published at the time of the
voting. Briefly, patients were considered ‘‘pro-
gressive’’ when they presented one of the three
following criteria despite treatment for ILD:
clinically significant decline of lung function
[C 10% relative decline in forced vital capacity
(FVC) over the last 24 months]; a combination
of worsening lung function (C 5–\ 10% relative
decline in FVC over the last 24 months) plus
worsening respiratory symptoms or evidence of
increasing fibrosis on chest imaging; or a com-
bination of worsening respiratory symptoms
and evidence of increasing fibrosis on chest
imaging. This article is based on the opinion on
a specific topic based on the judgment of a
group of experts. For this purpose, there was no
need to collect any type of patient data or
information and obtaining an ethical commit-
tee approval was not needed. Also, as no patient
data were collected, there was no need to obtain
informed consent.
Statistical Analysis
The Delphi questionnaire included qualitative
and quantitative (discrete and continuous)
items. Qualitative items were evaluated with a
Likert-type nine-position scale, where 1 was
‘‘completely disagree’’ and 9 ‘‘completely agree’’.
The results were grouped into three categories
of agreement: ‘‘disagreement’’ (1–3), ‘‘neither
disagreement nor agreement’’ (4–6) and ‘‘agree-
ment’’ (7–9). Median score, mean, interquartile
range, and percentage of panellists in each
interval of agreement were calculated. ‘‘Con-
sensus’’ was defined as more than 75% of pan-
ellists voting within the ‘‘agreement’’ or
‘‘disagreement’’ intervals.
For numerical discrete variables, the per-
centage of panellists choosing a specific value
was determined, and ‘‘consensus’’ was defined as
[75% panellists agreeing to a specific value.
For numerical continuous variables, mean,
quartile 1 (Q1) and quartile 3 (Q3) (50% of the
central range of values obtained) were calcu-
lated, and the mean value was considered the
‘‘consensus’’ value.
Comparative analyses by specialty of the
panellists were carried out with the chi-square
test or analysis of variance (ANOVA) test for
categorical and continuous variables, respec-
tively. Data were analysed with IBM SPSS ver-
sion 22.0, and p\ 0.05 was considered
statistically significant.
Cost Analysis
Annual costs (per patient, by country and on
average) were estimated by a direct cost-analysis
study. Cost estimates were calculated as the
products of the estimated number of resources
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(i.e., visits, tests, treatments—including mean
doses and duration of treatment—and hospi-
talisations) used for diagnosis, annual number
of follow-ups and adverse events management,
management of exacerbations, and end-of-life
care obtained from the opinion of the panel-
lists, multiplied by their corresponding unit
cost.
For yearly cost calculation, cost of diagnosis
was based on the total diagnosis cost divided by
the average time to diagnosis. The cost calcu-
lation of the patient’s follow-up management
included hospitalisation and outpatient costs.
Similarly, cost of management of acute exacer-
bations included hospitalisation costs plus out-
patient costs during exacerbation follow-up.
This sum was then multiplied by the agreed
event frequency. For end-of-life event cost cal-
culation, the percentage of patients dying in the
intensive care unit (ICU), hospital, home or
nursing home was obtained. The cost of one
admission at the ICU and at the hospital was
assumed for the patients dying in this setting
and the sum of costs for outpatient visits, tests
and treatment resources was used for the
patients dying at home or at the nursing home.
Unit costs were given by local health econ-
omists, extracted from national or regional cost
databases, and published literature from the
respective countries. A list of sources per coun-
try can be found in the supplementary online
material (Supplementary Table S1).
When needed, unit costs were converted to
2019 value prices using the published consumer
price index (CPI). Final costs were converted
into euros for those countries not using this
currency.
Sensitivity Analysis
A series of univariate sensitivity analyses was
performed to estimate the impact of varying the
values of different input parameters on the cost
outcome results. Specific parameters were varied
one at a time across a plausible range, while the
remaining values were held at baseline values.
The parameters tested were the resources used
(Q1, median, and Q3 values) and the unit costs
for outpatient visits, hospitalisations, drugs,
laboratory tests, and imaging and other tests
(± 25%).
RESULTS
Characteristics of Participant Panellists
Of the 138 panellists invited to participate in
the survey, 40 specialists (32 pulmonologists
and 8 rheumatologists) completed the ques-
tionnaire for both rounds of the survey. Geo-
graphical distribution of participants was:
Belgium (n = 3), Denmark (n = 8), Greece
(n = 9), The Netherlands (n = 7), Portugal
(n = 8), Finland (n = 1), Norway (n = 2), and
Sweden (n = 2).
Panellists reported that a total of 7757
patients with fibrosing ILD attended their hos-
pitals or clinics in the last year, amongst which
2459 were IPF. Of the 5298 non-IPF fibrosing
ILD patients, 31.6% presented a progressive
fibrosing behaviour and 68.4% a non-/slow-
progressive fibrosing ILD.
Consensus on the Definition,
Management, and Impact of Progressive
Fibrosing ILD
The definition of progression as used in the
INBUILD trial [3, 15] reached large consensus
among panellists (84.8%, Fig. 1a).
The majority of panellists agreed that pro-
gression of the fibrosis can be found in a variety
of ILDs other than IPF and that these might
have a similar prognosis and clinical course
than IPF, although agreement was not reached
on similarity of survival between IPF patients
and patients with other progressive fibrosing
ILDs (Fig. 1a).
Panellists agreed that progressive fibrosing
ILD patients can suffer from exacerbations and
that these events directly impact survival, are
more frequent when the disease is severe, and
are the most impactful clinical events for the
quality of life of progressive fibrosing ILD
patients. There was no consensus on the fact
that exacerbation rates are similar across all
types of progressive fibrosing ILD.
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Experts did not reach a consensus on the
need for specific treatment for lung deteriora-
tion for each subtype of disease. There was a
consensus to treat progressive fibrosing ILD
patients with anti-fibrotic drugs at diagnosis
should they be proven to be effective and safe,
and concurrently with cyclophosphamide/my-
cophenolate mofetil, (CYC/MMF) but not as
first-line treatment or after CYC/MMF (Fig. 1b).
Fig. 1 a Consensus on clinical course and impact on quality of life of progressive fibrosing ILD. b Consensus on
exacerbations, clinical objectives, management, and pharmacological treatment for progressive fibrosing ILD
Adv Ther
All respondents agreed that there is a high
unmet need for a safe and effective treatment
for patients with progressive fibrosing ILDs
(Fig. 1b). There was a consensus on the treat-
ment goals, which were to prevent lung deteri-
oration, prevent exacerbations, preserve quality
of life, and increase survival.
Resources Used for Diagnosis
Time from first symptoms to definite diagnosis
of non-IPF fibrosing ILD was 2.3 years (mean
[Q1–Q3]: 2.3 [2–3] years). For definite diagnosis,
panellists indicated a mean [Q1–Q3] of 3.6 [3–4]
total visits, 9.1 [7–9] laboratory tests, and 9.5
[6–12] imaging and other tests (Table 1). Among
the specialists involved in making the diagno-
sis, pulmonologists were considered the most
important (data not shown).
Resources Used for Follow-Up
Management and Maintenance Treatment
Panellists agreed that pulmonologists are the
main responsible physicians for the monitoring
of non-IPF fibrosing ILD patients (data not
shown). Overall, number of visits and tests
(laboratory and imaging and other tests) used
for follow-up of progressive fibrosing ILD
patients was reported to be higher than for
patients with non-/slow-progressive fibrosing
ILD (Table 2). Similarly, panellists reported
more hospitalisations per patient during the last
year, and of longer duration, in patients with
progressive fibrosing ILD than in patients with
the non-/slow-progressive form of the disease
(4.4 vs. 2.6 hospitalisations per patient and
5.9 days vs 3.9 days of duration in average,
respectively, according to the panellists).
Regarding maintenance treatment, 50% of
the panellists have a ‘‘watch and wait’’ approach
for patients with non-/slow-progressive fibros-
ing ILD (21.8% of patients), while only 22.5%
adopted this approach for progressive fibrosing
ILD patients (6.2% of patients). Treatment of
non-/slow-progressive fibrosing ILD patients
mainly consisted of systemic corticosteroids
(32.1% of patients), mycophenolate mofetil
(21.4% of patients), and azathioprine (19.6% of
patients). For progressive fibrosing ILD, a similar
treatment pattern was observed but at a higher
rate (45.4%, 39.0%, and 24.9%, respectively).
The use of oxygen therapy is more than four
times higher in progressive fibrosing ILD com-
pared with the non-/slow-progressive forms of
the disease (29.8% of patients vs. 7.1%). Overall,
pulmonary rehabilitation sessions were indi-
cated 1.4 times more often (Table 3). The
number of patients who received lung trans-
plantation in the last year was approximately
seven times higher in progressive fibrosing ILD
patients than in patients with the non-/slow-
progressive form of the disease (Table 3).
Lastly, panellists estimated that 73.1% of
progressive fibrosing ILD patients would benefit
from antifibrotic agents if their efficacy and
safety were proven and if they had a regulatory
label in that indication.
Panellists reported describing adverse events
(AE) using tumour necrosis factor (TNF) inhibi-
tors, systemic corticosteroids, antifibrotics, and
immunomodulatory agents in 56.7%, 25.0%,
22.1%, and 16.2% of the patients, respectively.
When patients were reported to have an AE, the
rate of hospitalisation was 19.0%, 100.0%,
50.0%, and 11.6% for immunomodulatory
agents, cyclin-dependent kinase (CDK) inhibi-
tors, TNF inhibitors, and systemic corticos-
teroids, respectively. For antifibrotics, anti-
inflammatory agents, antibiotics, and long-term
oxygen, the rate of hospitalisation when an AE
occurred was\5% and most AEs were indicated
to be managed in an outpatient setting (Sup-
plementary Table S2).
Resources Used for Exacerbations
Panellists estimated that the number of patients
who had suffered one acute exacerbation during
the last year was more than two times higher in
progressive fibrosing ILD patients than in
patients with non-/slow-progressive fibrosing
ILD (mean [Q1–Q3]: 19.7% [10–28] vs. 7.2%
[2–10], respectively). The number of patients
who had suffered more than one exacerbation
during the last year was more than three times
higher in progressive fibrosing ILD patients
than in patients with non-/slow-progressive
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Table 1 Description of resources used for diagnosis of non-IPF fibrosing ILD
Resource Number of visits or tests
Mean [Q1–Q3]
Number of panellists who
estimated a value per resourcea
Number of visits per patient, total 3.6 [3–4]
Pulmonologist 2.4 [2–3]* 37
Rheumatologist 1.2 [0–2] 34
Dermatologist 0.2 [0–0] 33
Number of laboratory tests per patient, total 9.1 [7–9]
Complete blood count 1.4 [1–2] 37
Sedimentation rate 1.0 [1–1] 37
Hepatic profile 1.1 [1–1] 37
Creatine-phosphokinase (CPK) 1.1 [1–1] 37
Angiotensin-converting enzyme (ACE) 0.9 [1–1] 37
Rheumatoid factor 1.1 [1–1] 37
Antinuclear antibodies 1.1 [1–1] 37
Urinalysis 0.8 [0–1] 37
Other 0.9 [0–1] 26
Number of imaging or other tests per patient, total 11.3 [8–14]*
Chest radiography 1.1 [1–1] 38
High-resolution computed tomography 1.3 [1–2] 38
CT pulmonary angiogram 0.2 [0–0] 38
Bronchoscopy 0.9 [1–1]** 38
Sputum assessment 0.2 [0–0]* 37
Bronchoalveolar lavage 0.9 [1–1] 37
Transbronchial biopsy 0.5 [0–1]* 37
Ventilation/perfusion scan 0.1 [0–0] 37
Blood gases 0.8 [0–1] 37
Spirometry 1.5 [1–2] 37
Body plethysmography 1.2 [1–2]** 37
Diffusing capacity of carbon monoxide 1.5 [1–2] 37
6-min walk test 1.1 [1–1] 37
Other 0.4 [0–1] 20
a All panellists (N = 40) answered all questions. When the number was\ 40, the remaining panellists filled in ‘‘I don’t
know’’
Comparison per specialty (pulmonologists vs. rheumatologists): *p\ 0.05; **p\ 0.01; ***p\ 0.001
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Table 2 Description of resources used during follow-up of patients with non-/slow-progressive fibrosing ILD and patients
with progressive fibrosing ILD
Resource Number of visits or tests
Mean [Q1-Q3]
Number of panellists who
estimated a value per resourcea
Non-/slow-
progressive fibrosing
ILD
Progressive
fibrosing ILD
Number of visits per patient, total 4.7 [3–5] 7 [5–9]
Pulmonologist 2.7 [2–4]*** 3.7 [3–4]** 38
Rheumatologist 0.9 [0–1] 1.1 [0–2]* 33
Dermatologist 0 [0–0] 0 [0–0] 29
Nurse (or other healthcare professionals) 0.8 [0–1] 1.2 [0–2] 31
Pulmonologist home visit 0.1 [0–0] 0.2 [0–0] 30
Home nurse (or other homecare
healthcare professionals)
0 [0–0] 0.2 [0–0] 28
Social workers 0.1 [0–0] 0.3 [0–1] 28
Emergency room visits 0.7 [0–1] 1.2 [0–2] 26/27
Number of laboratory tests per patient,
total
10.6 [6–12] 13.6 [9–19]
Complete blood count 2.5 [1–4] 3.4 [2–4] 33/34
Sedimentation rate 1.5 [0–3] 1.9 [0–3] 32/33
Hepatic profile 2.6 [1–4] 3.4 [2–4] 32/33
Creatine phosphokinase (CPK) 1.2 [0–2] 1.4 [0–2] 32/33
Angiotensin-converting enzyme (ACE) 0.5 [0–1] 0.6 [0–1] 32/33
Rheumatoid factor 0.6 [0–1] 0.7 [0–1] 33/34
Antinuclear antibodies 0.7 [0–1] 0.7 [0–1] 32/33
Urinalysis 1.1 [0–2] 1.3 [0–2]* 32/33
Other 0.3 [0–0] 0.8 [0–0.5] 19/20
Number of imaging or other tests per
patient, total
14.2 [9–22]* 19 [15–23]*
Chest x-ray 1.3 [1–2] 1.6 [1–2]* 34
High-resolution computed tomography
(HRCT)
0.9 [1–1] 1.3 [1–1] 33/34
Computed tomography pulmonary
angiogram
0 [0–0] 0.1 [0–0] 31/32
Bronchoscopy 0.4 [0–1] 0.7 [0–1] 31/32
Sputum assessment 0.3 [0–0] 0.4 [0–1] 31/32
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Table 2 continued
Resource Number of visits or testsMean [Q1-
Q3]
Number of panellists who
estimated a value per resourcea
Non-/slow-
progressive fibrosing
ILD
Progressive
fibrosing ILD
Bronchoalveolar lavage 0.5 [0–1] 0.6 [0–1] 31/32
Transbronchial biopsy 0.0 [0–0] 0.2 [0–0] 31/32
Surgical lung biopsy 0.4 [0–0] 0.3 [0–0] 31/32
Cryobiopsy 0.2 [0–0] 0.3 [0–0] 31/32
Ventilation/perfusion scan 0.0 [0–0] 0.3 [0–0] 30/31
Blood gases 0.9 [0–1.1] 1.5 [1–2] 33
Respiratory function tests 2.3 [1–3]* 2.9 [2–4]*** 31
Spirometry 2.1 [1–3]** 2.7 [2–4]** 33
Bodyplethysmography 1.4 [0–2] 1.5 [0.5–2.5] 32
Diffusing capacity of carbon monoxide 2.2 [1–3]** 2.8 [2–4]*** 33
6-min walk test 1.3 [1–1] 1.5 [1–2] 33
Other 0.1 [0–0] 0.1 [0–0] 17
Number of hospitalisations per patient,
total
2.6 [0–4] 4.4 [2–5]
Number of hospital admissions 1.5 [0–2] 1.9 [1–2] 30
Mean duration of a hospital admission
(days)
3.9 [2–5] 5.9 [4–7] 14b
Number of hospital admissions at the
pulmonary department
1.1 [0–1.5] 2.2 [1–2] 28
Mean duration of a hospitalisation at the
pulmonary department (days)
4.3 [3–5] 6.2 [4–7] 13b
Number of hospital admissions at the
intensive care unit
0.1 [0–0] 0.5 [0–1] 27
Mean duration of a hospitalisation at the
intensive care unit (days)
2.5 [2–3] 3.4 [2–5] 2b
a Except when indicated (b), all panellists (N = 40) answered the question. When the number is\ 40, the remaining
panellists filled in the option ‘‘I don’t know’’. When two values are indicated, the left value indicates the number of panellists
who gave a value for non-/slow-progressive F-ILD and the right value the number of panellists who gave a value for
progressive fibrosing ILD
b Not all panellists answered the question. Here, the number of respondents is indicated
Comparison per specialty (pulmonologist vs. rheumatologist): *p\ 0.05; **p\ 0.01; ***p\ 0.001
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Table 4 Description of resources used for exacerbations of non-IPF fibrosing ILD
Resource Number of visits
or tests
Mean [Q1–Q3]
Number of panellists who estimated a
value per resourcea
Number of visits per patient, total 6.7 [4–9]
Pulmonologist 3.2 [2–4] 36
Rheumatologist 0.8 [0–1]*** 32
Dermatologist 0 [0–0] 31
Nurse (or other healthcare professionals) 1.2 [0–2] 30
Pulmonologist home visit 0.1 [0–0] 33
Home nurse (or other homecare healthcare
professionals)
0.3 [0–0] 33b
Emergency room visit 1.8 [1–2] 32b
Number of laboratory tests per patient, total 11.5 [8–12]
Complete blood count 3.4 [2–4] 34
Sedimentation rate 1.5 [0–2] 33
Hepatic profile 2.8 [2–4] 33
Creatine phosphokinase (CPK) 1.6 [0–2]* 33
Angiotensin-converting enzyme (ACE) 0.5 [0–0] 33
Rheumatoid factor 0.3 [0–1] 33
Antinuclear antibodies 0.4 [0–1] 33
Urinalysis 1 [0–1] 33
Other 0.3 [0–0] 23
Number of imaging or other tests per patient, total 19.8 [12–24]
Chest x-ray 2.1 [1–3] 35
High-resolution computed tomography (HRCT) 1.4 [1–1.3]* 35
Computed tomography pulmonary angiogram 1.0 [0–1] 34
Bronchoscopy 0.9 [0–1] 33
Sputum assessment 1 [0–1.5] 33
Bronchoalveolar lavage 0.9 [0–1] 34
Transbronchial biopsy 0.1 [0–0]*** 33
Surgical lung biopsy 0.0 [0–0] 33
Ventilation/perfusion scan 0.2 [0–0] 33
Blood gases 3.1 [1–4] 34
Respiratory function tests 2.0 [0–3] 34
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fibrosing ILD (6.1% [0–10] vs. 1.7% [0–2],
respectively).
On average, exacerbations and their follow-
up accounted for a mean [Q1–Q3] of 6.7 [4–9]
visits to healthcare professionals, 11.5 [8–12]
laboratory tests, 19.8 [12–24] imaging and other
tests, and 6 [2–6] hospital admissions (Table 4).
The main agents used to treat exacerbations
were antibiotics, prednisone, and methylpred-
nisolone (in 82% [75–100], 45.9% [0–100], and
44.5% [0–80] of the patients with acute exacer-
bation, respectively).
End-of-Life Care
Lastly, panellists estimated that palliative care is
administered for 6.1 months [3–6] in patients
with progressive fibrosing ILD, mostly in hos-
pitals (39.8%) or at home (35.6%).
Burden of Disease: Cost Analysis
Overall, the total annual costs per progressive
fibrosing ILD patient were 1.8 higher than the
costs per patient with the non-/slow-progressive
form of the disease, with an average of
€34,530.08 for progressive fibrosing ILD vs.
€18,745.57 for non-/slow-progressive fibrosing
Table 4 continued
Resource Number of visits
or testsMean
[Q1–Q3]
Number of panellists who estimated a
value per resourcea
Spirometry 2.0 [0–3] 34
Body plethysmography 1.2 [0–1] 33
Diffusing capacity of carbon monoxide 1.9 [0–3] 34
6-min walk test 0.6 [0–1] 34
Oxygen therapy 2.1 [1–2] 32
Other 0.1 [0–0] 17
Number of hospitalisations per patient, total 6 [2–6]
Number of hospital admissions 2.4 [1–3] 31
Mean duration of a hospital admission (days) 8.2 [6–10 29b
Number of hospital admissions at the pulmonary
department
2.9 [1–3] 29
Mean duration of a hospitalisation at the pulmonary
department (days)
7.2 [4–10] 27b
Number of hospital admissions at the intensive care
unit
0.9 [0–1] 29
Mean duration of a hospitalisation at the intensive
care unit (days)
4.8 [3–7] 12b
a Except when indicated (b), all panellists (N = 40) answered the question. When the number was\ 40, the remaining
panellists filled in the option ‘‘I don’t know’’
b Not all panellists answered the question. Here, the number of respondents is indicated
Comparison per specialty (pulmonologist vs. rheumatologist): *p\ 0.05; **p\ 0.01; ***p\ 0.001
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ILD (Table 5). Among follow-up costs, costs per
visits, hospitalisations, and tests were the main
cost drivers (data not shown).
Sensitivity Analyses
Q1 and Q3 values for healthcare resource use
had the most impact on the cost of the disease.
The cost of both forms of fibrosing ILD was
more sensitive to lower use of resources (Q1).
The most important cost driver was hospitali-
sation, for which a variation of 25% of costs
represented an overall variation of 17% of total
yearly costs (Fig. 2).
Burden of Disease: Impact on Quality
of Life
Panellists agreed that progressive fibrosing ILD
negatively impacts both patients’ and unpaid
carers’ quality of life. Up to 45.6% of patients
suffer fatigue according to the panellists. The
most common comorbidities reported by the
panellists included pulmonary infection
(29.3%), depression (27.2%), osteoporosis
(20.3%), and pulmonary hypertension (19.8%)
(Supplementary Table S3). Experts agreed that
quality of life of progressive fibrosing ILD
patients is related to lung function, and[ 93%
of respondents agreed that progressive fibrosing
ILD affects patients’ quality of life on quality of
life subdomains, i.e. emotional, social, and
Fig. 2 Univariate deterministic sensitivity analysis
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financial domains (Fig. 1a). Similarly, 85 to 90%
of panellists agreed that progressive fibrosing
ILD impacts unpaid carers’ quality of life in
terms of sleep and health, daily activities,
emotional well-being, social life, and finances
(data not shown).
Panellists estimated that 71.2% of their pro-
gressive fibrosing ILD patients are retired and
that 26.7% had retired early because of illness
(data not shown). Overall, respondents esti-
mated that 19.6% and 48.1% of non-/slow-
progressive vs. progressive fibrosing ILD
patients, respectively, had total permanent dis-
ability and 8.8% and 22.8% lost their job
because of disability, respectively (Supplemen-
tary Table S4). Finally, it was reported that
20.3% of patients required support from a paid
carer, for an average duration of 8 h per week,
while 60.5% of patients needed support from an
unpaid carer such as a partner, family member,
or neighbour, for 29.8 h per week (data not
shown).
DISCUSSION
Non-IPF fibrosing ILD affects a significant
number of patients; however, little is known
about its management and burden as well as the
effect of disease progression on patients’ quality
of life, healthcare resource use, and costs. The
results of this Delphi survey show a significant
effect of disease progression in fibrosing ILD
patients’ prognosis and quality of life, and on
the economic burden of the disease.
Panellists agreed that progression of fibrosis
can occur in 13–40% of patients with different
fibrotic ILDs, including those with connective
tissue disease-associated ILD (CTD-ILD)—such
as systemic sclerosis-associated ILD (SSc-ILD);
rheumatoid arthritis-associated ILD (RA-ILD)
and mixed CTD-ILD; chronic fibrosing hyper-
sensitivity pneumonitis; idiopathic non-specific
interstitial pneumonia; unclassifiable idiopathic
interstitial pneumonia; sarcoidosis and expo-
sure-related ILD. In our study, physicians
reported that approximately a third of their
non-IPF fibrosing ILD patients were progressive.
Progression of fibrosis in ILD has been asso-
ciated with poor prognosis [1, 5]. A recent
physicians’ survey estimated that the mortality
of progressive fibrosing ILD patients is similar to
that of IPF patients, with a median of 4–5 years
of survival from diagnosis [5]. Interestingly, in
our study panellists did not reach a consensus
on it, but they agreed that progressive fibrosing
ILD has a similar prognosis and clinical mani-
festations to IPF, especially in patients with the
UIP pattern. This could be because there is still
limited evidence on the survival of PF-ILD
patients especially when other organs are
involved, while a rapid decline of lung func-
tions and exacerbations occur in both PF-ILD
and IPF patients.
Acute exacerbations of IPF are clinically
meaningful events associated with poor prog-
nosis and increased mortality [16]. Similarly,
available data suggest that exacerbations of
progressive fibrosing ILD associate with an
increase of hospitalisations and decrease of
survival [17]. Panellists did not reach consensus
regarding the similarity of exacerbation rates
across different types of progressive fibrosing
ILD, but they reported more exacerbations in
progressive fibrosing ILD patients than in
patients with non-/slow-progressive fibrosing
ILD. The percentage of progressive fibrosing ILD
patients who suffered at least one exacerbation
in the last year more than doubled that of those
with non-slow progressive fibrosing ILD. In
agreement with the literature [17], panellists
agreed that exacerbations of progressive fibros-
ing ILD directly impact patient’s quality of life,
disease progression, and survival. Moreover,
physicians reported that progression had a sig-
nificant impact on quality of life not only for
progressive fibrosing ILD patients but also for
patients’ unpaid carers. Progression affected
daily functioning and had a social and emo-
tional impact on both groups.
In this study, a variety of treatments pre-
scribed to progressive fibrosing ILD patients was
observed. This heterogeneity might be
explained by the lack of an approved treatment
for the disease. In addition, this is a cluster of
various diseases. Systemic corticosteroids were
prescribed for 62.5% and 67.5% of patients with
non-/slow-progressive fibrosing ILD and pro-
gressive fibrosing ILD, in monotherapy or in
combination, even though there is little
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evidence of their efficiency for these diseases.
For progressive fibrosing ILD, mycophenolate
mofetil, which showed positive results in a
phase-II trial in SSc-ILD [18], was the most
commonly prescribed drug.
Panellists agreed that there is an unmet need
for a safe and effective treatment for progressive
fibrosing ILD patients. Recently, and after the
second wave of voting was analysed, results
from two clinical trials testing the effect of
antifibrotic agents on disease progression in
non-IPF fibrosing ILD patients have been pub-
lished [15, 19]. Although it was impossible to
apply the prespecified statistical model for
analysis of the primary end point, key sec-
ondary end point analysis of a double-blind,
placebo-controlled, phase 2 trial suggest that
pirfenidone may reduce the decline in FVC in
patients with unclassifiable progressive fibros-
ing ILD [19]. Moreover, in the INBUILD trial, a
double-blind, placebo-controlled, phase 3 trial,
nintedanib showed efficacy in reducing the
decline in FVC (- 80.8 ml/year) compared with
placebo (- 187.8 ml/year) (p\0.001), with
consistent efficacy across patients with and
without a usual interstitial pneumonia-like
pattern [15]. In our study, panellists estimated
that 73.1% of progressive fibrosing ILD patients
and 32.2% of patients with non-/slow-fibrosing
ILD would benefit from antifibrotic agents. The
panellists answered the questionnaire before
these data were available; hence, results might
differ once new molecules are registered and
available to patients.
Management of progressive fibrosing ILD is
complex and requires input from multiple spe-
cialists and specialist visits, tests, and treat-
ments. Progressive fibrosing ILD patients had
more follow-up visits and needed more treat-
ment than patients without progression,
including pharmacological treatment, and
oxygen therapy (percentage of patients receiv-
ing treatment was approximately four times
higher for progressive fibrosing ILD than for
non-/slow-progressive fibrosing ILD), pul-
monary rehabilitation (approximately 1.4 times
higher), and lung transplantation (approxi-
mately 7 times higher). On average, total
annual costs per progressive fibrosing ILD
patient were 1.8 times higher than annual costs
per patient with the non-/slow-progressive form
of the disease. Overall, progression in fibrosing
ILD significantly increased the costs of follow-
up management and management of
exacerbations.
This study has limitations. A Delphi ques-
tionnaire was used to estimate management
and healthcare resource use of progressive
fibrosing ILD patients, and thus the estimated
values depend on panellists’ clinical experience,
specialty, and practice, which may not be fully
representative of general clinical practice in all
the participating countries, especially in the
Nordic countries where a limited number of
panellists were involved. Pulmonologists were
considered as the most important figure for the
diagnosis and management of patients. As some
types of ILD such as SSc-ILD or RA-ILD can be
managed by rheumatologists, their involve-
ment was considered necessary and their par-
ticipation accounted for less than a quarter of
the pool of panellist. Management patterns may
differ according to the specialty and combining
results from both pulmonologists and rheuma-
tologists may generate bias in the analysis.
Second, the healthcare resource use data from
different countries were averaged, and therefore
the differences in progressive fibrosing ILD
management between countries could not be
detected. Moreover, it should be noted that cost
comparison between countries should be done
with caution. The costs of progressive fibrosing
ILD were calculated per country by applying
local costs, following recommendations of local
health economists. Official prices differ between
countries; for instance, in The Netherlands and
Belgium official prices for medicines are phar-
macy purchasing prices and include value-
added tax (VAT) while in Denmark they do not
include VAT.
The study results are based on the opinion of
40 panellists specialised in pulmonology and
rheumatology. As data of healthcare resource
use in primary and secondary care are not
available in all participating countries, the Del-
phi method approach has allowed us to better
understand the management and burden of
disease of progressive fibrosing ILD.
Adv Ther
CONCLUSIONS
Based on a European survey, this study shows
that progression of fibrosing ILD is associated
with increased exacerbations, worse patient
quality of life, and increased healthcare resource
use and costs. Agents that prevent disease pro-
gression would benefit patients and reduce the
burden of disease.
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